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Abstract: A behavioral tolerance to the ambulation-increasing effect of scopolamine (SCP: 2 mg/kg s.c.), a muscarinic 
anti-cholinergic drug, was induced following the repeated administration to mice at 3-day intervals.  The combined 
administration of SCP + bethanechol (BET: 0.01, 0.03, 0.1 and 0.3 mg/kg s.c.), a peripheral muscarinic cholinergic drug, 
resulted in sensitization, although the single treatment with 0.03-0.1 mg/kg of BET did not modify the ambulation-increasing 
effect of SCP at the first administration.  In addition, the treatment with BET (0.1 mg/kg) at post-SCP period of 5-20 min also 
induced the sensitization to SCP after the repeated administration.  The post-SCP treatment with BET at 30 min and later 
produced the tolerance to SCP.  The repeated administrations of BET alone did not change the sensitivity to the ambulation-
increasing effect of SCP.  Furthermore, the mice showing sensitization to SCP + BET, but not tolerance to SCP, demonstrated 
a cross-sensitization to methamphetamine (2 mg/kg s.c.).  These results suggest that the tolerance to SCP is produced by the 
interaction of the stimulation of central dopaminergic system (reward effect) through the blockade of peripheral muscarinic 
cholinergic receptors (harmful effect), and that the latter effect overwhelms the former effect of SCP.  It is also suggested 
that the selective inhibition of the peripheral anti-cholinergic effect of SCP increases the dependence liability of SCP, and 
psychotoxicity of anti-cholinergic drugs including SCP and psychomotor stimulant drugs such as methamphetamine.
(Reprint request should be sent to Hisashi Kuribara)
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Introduction
Scopolamine (SCP) has an antagonistic action on both 
the peripheral and central muscarinic acetylcholine recep-
tors, and blocks the parasympathomimetic nervous system 
(Brunton et al., 2008).  It has been considered that the 
blockade of central cholinergic systems (Mathura et al., 
1997; Shannon and Peters, 2001; Chintoh et al., 2003), and 
the stimulation of central dopaminergic systems through 
the blockade of central muscarinic cholinergic receptors 
(Fink and Morgenstern, 1980) are involved in the SCP-
induced hyperactivity.
SCP is self-administered by animals (Glick and Goido, 
1982; Rasmussen and Fink-Jensen, 2000), and a short-term 
recreational use of SCP (Sussam and Ames, 2001) and 
Angel’s
 trumpet (Greene et al., 1996) which is a plant con-
taining muscarinic anti-choinergic drugs such as SCP and 
atropine has been reported, indicating dependence liabili-
ty of SCP.
The repeated administrations of psychomotor stimulant 
drugs such as methamphetamine and cocaine (Kuribara 
and Hirabayashi, 1985; Kuribara, 1996, 2009) to mice 
induce sensitization to their ambulation-increasing effect. 
It has been considered that the processes and conditions of 
behavioral sensitization to psychomotor stimulant drugs 
are intimately related not only to the dependence liability 
of drugs (Piercem and Kumaresan, 2006) but also the 
psychotoxicity (Robinson and Becker, 1986; Tadokoro and 
Kuribara, 1986; Pert et al., 1990) induced by the repeated 
use of such drugs.  Mesolimbic dopaminergic systems (Van 
der Heuval and Pasterkamp, 2008) play important roles in 
the behavioral and psycho-pharmacological activities, 
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including motivation (Matsumoto and Hikosaka, 2009), 
and drug dependence and abuse (Schultz, 2002; Piercem 
and Kumaresan 2006; Berridge, 2007; Ikemoto, 2007).
However, different from the characteristics of psychomo-
tor stimulant drugs, it has been reported that the repeated 
administration of SCP to the mice at intervals of 1 day or 
longer resulted in a significant tolerance to the ambulation-
increasing effect (Kuribara and Tadokoro, 1983, 1987), 
and that the tolerance was induced at an early post-SCP 
period (Kuribara, 2013) dependent on the environmental 
situations (Kuribara, 2011).  The peripheral anti-cholinergic 
action of SCP causes harmful symptoms such as dry mouth 
and eyes (Bruston et al., 2008).  It is therefore possible 
following the repeated administration of SCP that the 
peripheral harmful symptoms overwhelm the reward 
effect of SCP produced by the indirect stimulation of the 
central dopaminergic systems through blockade of the 
muscarinic cholinergic receptors, and that such interaction 
plays an important role in the induction of behavioral 
tolerance to the ambulation-increasing effect of SCP.
To confirm this possibility, the modification by 
bethanechol, a peripheral muscarinic acetylcholine receptor 
agonist, of the SCP-induced behavioral stimulation follow-
ing the repeated administration was evaluated in mice. 
In addition, challenge administration of methamphetamine 
was carried out to the mice pretreated with the repeated 
administrations of SCP + BET for five times at interval of 
3 days to assess the change in the sensitivity to the psycho-
toxicity of psychomotor stimulant drugs.
Materials and Methods
 Animals
The experimental animals used were male mice of the 
ddY strain (SLA Japan, Hamamatsu).  They were used at 6 
weeks of age and a weight of 25-28 g.  Groups of 10 mice 
each had been housed in Polycarbonate cages (20W X 25L 
X 15H cm) with free access to a solid diet (MF: Oriental 
Yeast, Tokyo) and tap water except during the behavioral 
tests.  The breeding rooms were controlled to temperature; 
23 ± 1 °C, relative humidity; 55 ± 3 %, and a 12:12-hr 
light-dark cycle; lights on between 06:00-18:00 hr.  The 
temperature and relative humidity of experimental room 
were almost the same as those of the breeding room.
All the experimental treatments mentioned below were 
carried out according to “The Guiding Principles for the 
Care and Use of Laboratory Animals” of The Japanese 
Pharmacological Society.
Apparatus
The apparatus for measurement of the ambulatory activity 
of mice was a tilting-type “ambulometer” having 10 tilting-
type Plexiglas activity cages of 20 cm in diameter and 15 cm 
in height (SMA-10: O’hara & Co., Tokyo).  The apparatus 
could selectively detect the horizontal movement, but not 
turning, or vertical movements such as rearing, head move-
ment or sniffing, of 10 mice.
Drugs
The drugs used were scopolamine hydrobromide (SCP: 
Sigma Chem., St.  Louis, MO), bethanechol chloride (BET: 
Sigma Chem.) and methamphetamine hydrochloride (MA; 
Philopon: Dainippon-Sumitomo Pharm., Osaka).  These 
drugs were dissolved in physiological saline, and subcutane-
ously (s.c.) administered at a constant volume of 0.1 ml/10 
g body weight of the mouse independent of the doses of 
drugs.  The doses of drugs were shown in the salt forms.
Experimental schedules
All the experimental treatments; the administration of 
SCP and BET, and measurement of ambulation of the 
mice, were carried out between 09:00-16:00 hr.
In the case of measurement of the activity of mice, they 
were individually put in the activity cages for 10 min, and 
then the administration of drugs was conducted.  The 
activity of each mouse was measured at intervals for 90 
and 180 min after administrations of SCP + BET and 
MA, respectively.
1) Repeated administration of SCP + BET and chal-
lenge administration of MA
Five groups of mice (10 mice each) were given SCP 
(2 mg/kg s.c.) + BET (0: saline, 0.01, 0.03, 0.1 and 0.3 mg/
kg s.c.) for 5 times at intervals of 3 days.  As the control 
administration, other 5 groups of 10 mice each were given 
BET (0, 0.01, 0.03, 0.1 and 0.1 mg/kg) alone.  After each 
drug administration, the ambulatory activity of the mouse 
was measured for 90 min.
Three days after the final (5th) pretreatment with SCP 
(2 mg/kg) + BET (0, 0.01, 0.03, 0.1 and 0.3 mg/kg) or 
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BET (0, 0.01, 0.03, 0.1 and 0.3 mg/kg) alone, MA (2mg/kg 
s.c.) was challenge-administered to all groups of mice, and 
their ambulatory activities were measured for 180 min.
Other 10 mice of drug-naïve were administered MAP 
(2 mg/kg s.c.) as the control.
2) Repeated administration of SCP + post-SCP treat-
ment with BET
 Seven groups 10 mice each were administered SCP 
(2mg/kg s.c.) 5 times at intervals of 3 days.  Each SCP 
administration was followed by the administration of BET 
(0.1 mg/kg s.c.) at 0 (simultaneous), 5, 10, 20, 30, 60 or 90 
min (immediately after the end of measurement of ambula-
tory activity), and the ambulatory activities were measured 
for 90 min.
Statistical analysis
The mean activity counts in each group were analyzed 
by one-way analysis of variance (ANOVA).  Post-hoc 
analyses were carried out by Bonferroni test.  Values of p 
less than 0.05 were considered significant.
Results
Repeated administration of SCP + BET and challenge 
administration of MA
Table 1 shows the mean overall activity counts of mice 
following repeated co-administration of SCP (2 mg/kg) + 
BET (0, 0.01, 0.03, 0.1 and 0.3 mg/kg) at 3-day intervals.
Although there was no significant difference in the 
activity counts at the first administration, SCP (2 mg/kg) 
alone induced progressive decrease in the ambulation-
increasing effect, SCP + BET (0.01 mg/kg) tended to 
increase the effect, and SCP + BET (0.03 and 0.1 mg/kg) 
induced a significant sensitization following the repeated 
administrations.
The mice given SCP + BET (0.3 mg/kg) showed signifi-
cantly lower activity count at the first administration, and 
no significant change in the activity count was demonstrated 
following the repeated administration.
The activity counts of the mice treated with BET alone 
were very low (10-39 counts) at the first administration, 
and no significant change in the activity counts was demon-
strated throughout the five repeated administrations (data 
not shown).  No significant change in the sensitivity to 
SCP was observed in the mice pretreated with BET (data 
not shown).
Table 2 shows mean 180 min activity counts following 
the challenge administration of MA to the groups of mice 
that had been pretreated with BET alone or SCP + BET.
The groups of mice pretreated with SCP or BET alone 
did not show significant change in the sensitivity to the 
challenge-administered MA.  In contrast, the groups of 
mice pretreated with SCP + BET showed significantly 
higher sensitivity to MA.
Repeated administration of SCP + post-SCP treatment 
with BET
As shown in Table 3, the activity counts at the first 
administration of SCP + post-SCP treatment with BET 
were almost the same among the groups of mice regardless 
of the doses of BET.  However, the repeated administration 
of SCP + post-SCP treatment with BET induced sensitiza-
tion when BET treatment was carried out at 0, 5, 10 and 20 
min, and tolerance when BET treatment was carried out at 
30, 60 or 90 min.
Table 1.   Mean activity counts of mice following the repeated co-administration of scopolamine  
(SCP: 2 mg/kg s.c.) + bethanechol (BET: 0, 0.01, 0.03, 0.1 and 0.3 mg/kg s.c.) for 5 times at 3-day intervals.
Doses of drugs 1st 2nd 3rd 4th 5th
SCP alone 523±61 262±28* 172±15* 124±15* 106±13*
SCP + BET (0.01) 557±71 510±67 565±55 455±86 416±67
SCP + BET (0.03) 572±67 668±71 785±89$ 793±80$ 817±92$
SCP + BET (0.1) 530±55 628±80 722±99$ 740±83$ 769±87$
SCP + BET (0.3) 312±57 363±49 389±47 413±59 431±61
N=10 in each group.  *: significantly lower (p<0.05) vs. the value at the 1st administration within group.   
$: significantly higher (p<0.05) vs. the value at the 1st administration within each group.
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Gross observation
The mice given BET alone and combination of SCP + 
BET (0.3 mg/kg) showed parasympathomimetic symptoms 
such as increase in saliva and tear.
Discussion
In consistent with the previous reports (Kuribara, 2011; 
Kuribara and Tadokoro, 1983, 1987), the repeated admin-
istration of SCP alone to the mice at intervals of 3 days 
induced tolerance to the ambulation-increasing effect. 
It has been considered that such tolerance to SCP is highly 
dependent on the environment, and that the peripheral 
anti-muscarinic symptoms play an important role in the 
induction of tolerance to SCP (Kuribara, 2011).  The 
central dopaminergic system (Fink and Morgenstern, 
1980) and cholinergic systems (Mathura et al., 1997; 
Shannon and Peters, 2001; Chintoh et al., 2003) are 
involved in the SCP-induced hyperactivity.  Generally, 
the repeated administrations of psychomotor stimulants 
Table 2.   Mean activity counts after the challenge-administration of methamphetamine (2mg/
kg s.c.) to the mice pretreated with scopolamine (2 mg/kg s.c.) + bethanechol (0, 0.01, 
0.03, 0.1 and 0.3 mg/kg s.c.) or bethanechol alone for 5 times at 3-day intervals.
Pretreatments Activity counts following methamphetamine
Saline 1756±219
Bethanechol 0.01 mg/kg 1692±241
0.03 1716±229
 0.1 1670±264
 0.3 1688±225
Scopolamine alone 1994±265
Scopolamine + Bethanechol 0.01 mg/kg 2356±309
Scopolamine + Bethanechol 0.03 2911±391*,$
Scopolamine + Bethanechol 0.1 3308±446*,$
Scopolamine + Bethanechol 0.3 2503±338
No treatment 1701±247
N=10 in each group.  *: p<0.05 vs. the value of saline-pretreated group.  $: p<0.05 vs. the value 
of mice pretreated with scopolamine alone.
Table 3.   Mean activity counts of mice following the repeated administration of scopolamine 
(SCP: 2 mg/kg s.c.) + post-SCP treatment with bethanechol (BET: 0.1 mg/kg s.c.) for 
5 times at 3-day intervals.
Doses of drugs 1st 2nd 3rd 4th 5th
SCP→(0min)→BET 550±76 689±81 759±98* 807±91* 837±99*
SCP→(5min)→BET 523±62 568±57 658±68 739±77* 840±85*
SCP→(10min)→BET 543±76 568±71 608±87 685±83 783±77*
SCP→(20min)→BET 552±67 628±52 660±70 643±93 715±72*
SCP→(30min)→BET 559±72 339±53$ 302±55$ 270±33$ 212±35$
SCP→(60min)→BET 591±85 213±42$ 137±22$ 141±30$ 133±24$
SCP→(90min)→BET 572±67 228±35$ 108±19$ 110±13$ 105±12$
N=10 in each group.  *: significantly higher (p<0.05) vs. the value at the 1st administration within 
group.  $: significantly lower (p<0.05) vs. the value at the 1st administration within each group.
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and narcotic analgesics to the mice induce significant 
sensitization to their ambulation-increasing effects through 
stimulation of the mesolimbic dopaminergic systems 
(Kalivas and Stewart, 1991; Kuribara, 1995).  The author 
reported that the induction of tolerance to the ambulation-
increasing effect of SCP was highly dependent on the 
interaction of the anti-cholinergic effect and the movement 
in the activity cage at an early post-SCP period (Kuribara, 
2011, 2013). 
Following to these pharmacological and behavioral 
evidences, it is supposed that the repeated administrations 
of SCP induce sensitization to its ambulation-increasing 
effect when the peripheral, but not central, muscarinic 
anti-cholinergic effect is selectively inhibited at an early 
post-SCP period.  To confirm this hypothesis, in this 
study, BET was used to selectively block the peripheral 
anti-cholinergic effect of SCP.
Although BET alone did not change the sensitivity to 
SCP, the mice treated with SCP + BET (0.03 and 0.1 mg/
kg) produced not only significant enhancement of the 
ambulation-increasing effect, but also cross sensitization 
to MAP.  In is also notable that the blockade of SCP 
tolerance by BET was effective when BET treatment was 
carried out at post-SCP period of 0-20 min.  This result is 
consistent with the previous report (Kuribara, 2011, 2013) 
that the induction of SCP tolerance could be attenuated by 
the physical restriction of ambulation or blockade of the 
anti-cholinergic effect of SCP during the early post-SCP 
period, suggesting that the combined experience of 
ambulation with the peripheral cholinergic symptoms 
at the early post-SCP period is important to induce the 
tolerance to SCP.
These findings strongly suggest that, although SCP 
stimulates central dopaminergic systems through the 
blockade of the muscarinic cholinergic receptors which 
may be related to the reward effect of SCP (Glick and Goido, 
1982; Rasmussen and Fink-Jensen, 2000), the harmful 
symptoms caused by peripheral muscarinic anti-cholinergic 
effect of SCP is much stronger than the reward effect.
The behavioral sensitization to psychomotor stimulants 
is considered to be intimately related to the reward effects, 
i.e., dependence liability (Piercem and Kumaresan 2006; 
Berridge, 2007; Ikemoto, 2007) and psychotoxicity (Robinson 
and Becker, 1986; Tadokoro and Kuribara, 1986; Pert et al., 
1990).
It is therefore suggested from the present results that, 
although severe dependence and abuse are rare for the 
muscarinic anti-cholinergic drugs (Sussam and Ames, 2001) 
and Angel’s trumpet (Greene et al., 1996; Brunton et al., 
2008), which contains muscarinic anti-cholinergic drugs 
such as SCP and atropine, blockade of the peripheral mus-
carinic cholinergic effect by the drugs such as bethanechol 
may enhance the dependence liability of anti-cholinergic 
drugs and the psychotoxicity of both anti-cholinergic drugs 
and psychomotor stimulants.
Conclusion
The induction of tolerance to the ambulation-increasing 
effect of SCP (2 mg/kg s.c.), an antagonist of muscarinic 
cholinergic receptors, was blocked, but rather induced 
sensitization when bethanechol (0.03 and 0.1 mg/kg s.c.), 
a peripheral muscarinic cholinergic drug, was treated at 
early post-SCP period of 0-20 min.  The repeated adminis-
trations of SCP + BET (0.03 and 0.1 mg/kg) resulted in the 
cross sensitization to methamphetamine (2 mg/kg s.c.). 
These results suggest that the tolerance to the ambulation-
increasing effect of SCP is induced by the experience of 
the harmful symptoms caused by the peripheral muscarinic 
cholinergic effect at the early post-SCP period.  It is also 
considered that the combined abuse of anti-muscarinic 
cholinergic drug with peripheral muscarinic drugs may 
increase the risks of abuse and psychotoxicity of not only 
anti-muscarinic cholinergic drugs but also psychomotor 
stimulants.
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末梢性ムスカリン型コリン作動薬bethanecholによるScopolamineの 
マウス移所運動促進作用に対する耐性形成の阻止
栗原　久
東京福祉大学短期大学部（伊勢崎キャンパス）
〒372-0831 伊勢崎市山王町2020-1
抄録： Scopolamine（SCP: 2 mg/kg s.c.）を3日間隔で反復投与すると、マウスの移所運動促進作用に対する耐性形成が形成
される。SCP（ムスカリン型抗コリン薬）と末梢ムスカリン型コリン作動薬のbethanechol（BET: 0.01, 0.03, 0.1, 0.3 mg/kg 
s.c.）を併用すると、初回投与時では、BETは高用量（0.3 mg/kg）を除いて、SCPの移所運動促進作用に影響しなかったが、
併用投与を反復すると増感現象が引き起こされた。SCP耐性の阻止および増感現象は、SCP投与から20分以内にBETを
処置した場合にのみ認められ、30分以降の処置では耐性が引き起こされた。BETおよびSCPの単独投与を反復経験した
マウスは覚せい剤methamphetamine（2 mg/kg s.c.）に対して感受性変化を示さなかったが、SCP ＋ BET（00.03, 0.1 mg/kg）
を反復経験したマウスは、覚せい剤に対して交差増感を示した。これらの結果は、抗コリン薬を投与した場合、中枢のムス
カリン型アセチルコリン受容体（MAchR）の阻害は報酬的効果（依存性）を現すが、同時に末梢のMAchRを介する嫌悪作用
によってブロックされること、また、末梢のMAchRを遮断しながら抗コリン薬を反復乱用すると、抗コリン薬に対しての
みならず、覚せい剤のような精神刺激薬の精神毒性が増強される可能性も示唆している。
（別刷請求先：栗原　久）
キーワード： Scopolamine, Bethanechol、Methamphetamine、行動耐性、中枢性と末梢性アセチルコリン神経系、精神毒性、
マウス

